Is Psoriasis Linked to Parkinson's? What the Research Actually Shows

Psoriasis is linked to a higher risk of Parkinson's disease. Studies show the increased risk ranges from 9% to 38% depending on the population and treatment status.

That sounds alarming. But the absolute risk is still low, under 1 in every 1,000 person-years. More importantly, the link appears to run through chronic inflammation, which means treating psoriasis aggressively may reduce neurological risk over time, not just improve your skin.

If you have longstanding psoriasis and want to understand what this connection means for your health, here's what the evidence actually shows.

What illness is connected to psoriasis beyond the skin?

Psoriasis is a systemic inflammatory condition, not just a skin problem. The same immune dysregulation that drives plaques on the skin can affect the heart, joints, kidneys, liver, and brain.

Psoriatic arthritis affects roughly 30% of people with psoriasis. Cardiovascular disease risk is significantly elevated. Depression and anxiety are common. And increasingly, research has examined the relationship between psoriasis and neurodegenerative conditions, including Parkinson's disease and dementia.

The connection to Parkinson's specifically has been examined in several large studies. A 2016 meta-analysis pooling data from four studies found that people with psoriasis had a 38% higher relative risk of developing Parkinson's compared to those without psoriasis. A large Korean cohort study following over 548,000 psoriasis patients found a hazard ratio of 1.09, meaning roughly a 9% elevated risk after controlling for other variables.

These aren't identical numbers, but they point in the same direction. The conditions most consistently linked to psoriasis are cardiovascular disease, metabolic syndrome, inflammatory bowel disease, and psychiatric disorders. Parkinson's now sits within this broader picture of systemic inflammatory burden.

Why would psoriasis increase Parkinson's risk?

The short version is inflammation. Chronic, low-grade systemic inflammation is the most plausible mechanism connecting the two conditions.

In Parkinson's disease, neuroinflammation plays a central role in the progressive loss of dopamine-producing neurons in the substantia nigra. The inflammatory molecules elevated in psoriasis, including TNF-alpha, IL-17, and IL-23, are also found at elevated levels in the brains of people with Parkinson's. The hypothesis is that sustained systemic inflammation from psoriasis may prime the brain's immune cells, contributing to neuronal damage over decades.

Oxidative stress is another factor. Psoriasis generates high levels of reactive oxygen species, and oxidative stress is a well-established driver of neurodegeneration. The gut-brain axis has also come up in research, given that gut microbiome disruption is present in both psoriasis and Parkinson's, though this remains an area of active investigation.

Shared genetics may also play a role, though the picture is complicated. Mendelian randomization studies, which use genetic variants to test causal relationships, have produced conflicting results. A 2022 study found that genetically determined psoriasis was associated with faster progression to dementia in existing Parkinson's patients.

But a 2024 European population study found no statistically significant causal genetic pathway between psoriasis and Parkinson's risk itself. What this likely means is that genetics alone don't drive the connection, but that inflammation triggered by psoriasis over time may be the actual mechanism.

Cardiometabolic confounders matter here too. Hypertension, type 2 diabetes, and obesity are all more common in people with psoriasis and all independently raise Parkinson's risk. Untangling these factors is difficult, which is why the studies produce different effect sizes depending on how well they control for them.

Does treating psoriasis reduce the risk?

This is the finding that most articles miss. It's arguably the most useful piece of information in this entire body of research.

The Korean cohort study found that psoriasis patients who weren't receiving systemic therapy had a significantly elevated risk of Parkinson's (HR 1.09). Patients who were on systemic therapy, meaning medications that reduce systemic inflammation throughout the body, didn't show a statistically significant elevated risk.

The hazard ratio for treated patients dropped to 1.04 and the confidence interval crossed 1, indicating no meaningful difference from the general population. This isn't a proven causal finding, and it can't be read as definitive proof that systemic treatment prevents Parkinson's.

But it's directionally consistent with the inflammation hypothesis, and it gives clinicians and patients a practical reason to take psoriasis treatment seriously beyond skin clearance. If the neurological risk is inflammation-driven, then controlling inflammation is the logical intervention.

Treating psoriasis as a systemic disease rather than a skin complaint is the single most actionable thing someone can take from this research. Biologics and other systemic agents aren't just about improving quality of life. They may be doing work in the background that shows up decades later.

What are two new early signs of Parkinson's to watch for?

Parkinson's has a long prodromal phase, meaning symptoms appear years before the classic motor signs. Two of the more recently recognised early indicators that people with psoriasis should know about are REM sleep behavior disorder and loss of smell.

REM sleep behavior disorder involves physically acting out vivid dreams, sometimes violently, because the normal muscle paralysis that occurs during REM sleep is absent. Research has consistently shown this is one of the strongest early predictors of Parkinson's and related conditions, sometimes preceding motor symptoms by a decade or more.

If you or a partner notices this pattern, it's worth raising with a neurologist regardless of psoriasis history. Loss of smell, or hyposmia, is another well-documented early sign. Many people with Parkinson's lose some or all sense of smell years before any movement problems develop.

This is easy to overlook because it seems unrelated to neurological function, but the olfactory system is one of the first areas affected by the protein aggregation that characterises Parkinson's pathology. Other prodromal features include constipation, depression, and subtle changes in handwriting or facial expression.

A 2023 German case-control study examining the full spectrum of prodromal features confirmed that these non-motor signs often predate diagnosis by years. For someone with longstanding psoriasis, none of these symptoms require immediate alarm.

But if several appear together, seeing a neurologist sooner rather than waiting for obvious motor symptoms is reasonable.

What are 4 surprising things that reduce Parkinson's disease risk?

Beyond treating psoriasis inflammation directly, there are several lifestyle factors with reasonable evidence behind them that most people don't associate with Parkinson's prevention.

Regular aerobic exercise consistently shows up in the research as protective. The effect is dose-dependent, meaning more exercise appears to confer greater benefit. The mechanism likely involves increased production of neurotrophic factors that support neuronal survival, plus anti-inflammatory effects that overlap with what psoriasis patients need anyway.

Caffeine consumption has been linked to reduced Parkinson's risk in multiple large epidemiological studies. The proposed mechanism involves adenosine receptor antagonism in the brain, which may have a protective effect on dopaminergic neurons. This doesn't mean coffee is a treatment, but it's one of the more consistent dietary signals in the literature.

Blood pressure control matters more than most people realise. Hypertension is an independent risk factor for Parkinson's, and it's also significantly more common in people with psoriasis. Managing it aggressively addresses two risk factors at once.

Urate levels have emerged from research as an unexpected factor. Higher serum urate is associated with slower Parkinson's progression and potentially lower risk, likely due to its antioxidant properties. This isn't a reason to pursue high urate levels clinically, but it points toward the broader role of oxidative stress in the disease.

What I find interesting about this list is that exercise, blood pressure management, and controlling systemic inflammation all benefit psoriasis patients independently. The overlap between managing psoriasis well and reducing Parkinson's risk isn't coincidental. It reflects that both conditions are downstream of the same inflammatory and metabolic processes.

What skin conditions are associated with Parkinson's disease directly?

This question usually gets answered backwards. Most articles focus on skin conditions that raise Parkinson's risk, but Parkinson's disease itself causes skin changes that can appear before or alongside motor symptoms.

Seborrheic dermatitis is the skin condition most consistently associated with Parkinson's disease. It presents as greasy, scaly patches typically on the scalp, face, and chest, and it's significantly more common in people with Parkinson's than in the general population.

The link is thought to involve autonomic nervous system dysfunction affecting sebaceous gland activity, plus potentially the overgrowth of Malassezia yeast in the context of immune changes. Rosacea has also been studied in relation to Parkinson's.

Some large epidemiological studies have found an association, possibly through shared neuroinflammatory mechanisms. Melanoma has a well-documented bidirectional relationship with Parkinson's.

People with Parkinson's have higher rates of melanoma, and melanoma patients have higher rates of Parkinson's. The connection appears to involve shared genetic pathways rather than one causing the other. Excessive sweating and oily skin are also common in Parkinson's due to autonomic dysfunction, though these are symptoms of the disease rather than separate conditions.

For someone with psoriasis who develops seborrheic dermatitis as a new or worsening problem, it's worth noting in the context of overall neurological risk, though seborrheic dermatitis alone is extremely common and doesn't warrant concern on its own.

The angle most articles miss

The headline number in this research, a 38% increased relative risk, sounds large but is misleading without context. Relative risk means very little without knowing the baseline.

The baseline incidence of Parkinson's in the general population is roughly 0.3% to 0.5% over a lifetime for most age groups. A 38% increase on a low baseline still gives you a very low absolute risk. The Korean study found 0.768 cases per 1,000 person-years in the psoriasis group versus 0.673 in controls. That's a small absolute difference.

The second thing most articles get wrong is framing this as something that happens to you. The Korean treatment data suggests it may be something you can influence. Psoriasis patients on systemic therapy didn't show elevated risk.

Whether that's because systemic therapy controls inflammation, because healthier patients are more likely to receive systemic therapy, or because the two conditions share a common cause that systemic therapy addresses isn't fully resolved. But the directional signal is there.

The third thing worth understanding is that the psoriasis-Parkinson's connection doesn't stand alone. It sits within a pattern of systemic inflammatory diseases that all show elevated neurodegenerative risk. Rheumatoid arthritis, inflammatory bowel disease, and psoriasis all share this signal.

The lesson isn't specific to psoriasis. It's that chronic systemic inflammation over decades has consequences in the brain, and controlling that inflammation has benefits that extend far beyond the primary condition.

FAQ

Should I get screened for Parkinson's if I have psoriasis?

Routine screening isn't currently recommended for psoriasis patients. The absolute risk increase is small. If you develop early signs like REM sleep behavior disorder, loss of smell, or subtle motor changes, raise these with your GP or a neurologist.

But psoriasis alone doesn't justify neurological workup.

Do psoriasis medications protect against Parkinson's?

The Korean cohort study found that psoriasis patients on systemic therapy didn't show a statistically significant elevated Parkinson's risk, while those not on systemic therapy did. This is observational evidence, not a clinical trial.

It suggests a protective signal worth taking seriously, but it hasn't been tested in a controlled way.

Is there a genetic overlap between psoriasis and Parkinson's?

Mendelian randomization studies have produced conflicting results. One found psoriasis genetics associated with faster Parkinson's progression; another found no significant causal link to Parkinson's risk in European populations.

Shared genetics likely play a partial role but don't fully explain the observational association.

Can managing my psoriasis reduce my overall neurological risk?

Based on current evidence, yes. Controlling systemic inflammation through treatment, managing blood pressure and glucose, exercising regularly, and maintaining a healthy weight all address the underlying risk factors that connect psoriasis to neurological disease.

These aren't speculative interventions; they have independent evidence behind each one.

How long does it take for psoriasis-related inflammation to affect the brain?

The current model suggests this is a decades-long process. Parkinson's typically develops in people over 60, and the prodromal phase can stretch back 10 to 20 years.

This means the inflammatory burden from psoriasis during midlife is likely the relevant window, which is one more reason early and sustained treatment matters.

What to do now

If you have psoriasis, here are the concrete steps that the evidence supports. First, discuss systemic treatment with your dermatologist if you're managing psoriasis with topical treatment alone, especially if your disease is moderate to severe.

The neurological data adds weight to an already strong clinical case for systemic therapy. Second, get your blood pressure, fasting glucose, and cholesterol checked and managed. These cardiometabolic factors compound the inflammatory risk from psoriasis.

Third, build regular aerobic exercise into your routine. It benefits psoriasis, cardiovascular health, and neurological resilience at the same time. Fourth, if you notice early neurological symptoms, particularly acting out dreams, unexplained loss of smell, or subtle changes in movement or handwriting, see a neurologist rather than waiting.

The link between psoriasis and Parkinson's is real but modest. The practical response isn't anxiety. It's treating psoriasis as the systemic inflammatory condition it actually is, and managing overall health accordingly.

About the author

Armstrong Lazenby

BSc (Human Nutrition) registered nutritionist. Bachelor of Science (Exercise Science major) Master of Sports Medicine.

Connect on LinkedIn →